

Special Issue

Advances in Cancer Immunology and Immunotherapy

Message from the Guest Editors

Discuss recent discoveries in tumor immunology as well as immunotherapy and the insights of those discoveries for further therapies. You are welcome to contribute a novel report, observation, or review article that focuses on (i) recent discoveries in tumor immunology and immunotherapy, (ii) a mechanistic explanation of the limitations of current tumor studies and immunotherapy, (iii) how to translate current knowledge into further therapies, (iv) future directions of tumor immunology studies, and (v) novel techniques as well as models which can help future tumor immunology studies. Update the community on the latest progress in tumor immunology as well as immunotherapy and point out future directions for researchers. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: tumor immunology, immunotherapy, and novel tumor models. We look forward to receiving your contributions.

Guest Editors

Dr. Wenjie Jin

Institute for Translational Bioengineering, F. Hoffmann-La Roche
Grenzacherstrasse 124, 4070 Basel, Switzerland

Dr. Zihé Huo

Department Biomedizin, University of Basel, DBM Hebelstrasse - FG
Guzman, Hebelstrasse 20, 4031 Basel, Switzerland

Deadline for manuscript submissions

closed (1 February 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/164579

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/

[vaccines](https://vaccines.mdpi.com)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).